Related Experiment Videos
[Multiple sclerosis. A report of a case treated with thymopentin]
A Borromei1, M Draghetti, L Guerra
1Istituto Clinica Neurologica, Università degli Studi, Bologna.
Minerva Medica
|May 1, 1995
Summary
This study details a late-onset multiple sclerosis (MS) case treated with thymopentin. The immunomodulator therapy significantly improved the patient's clinical symptoms and autonomy.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Atypical MS presentations, including late onset, pose diagnostic and therapeutic challenges.
- Standard treatments often involve corticosteroids and adrenocorticotropic hormone (ACTH) therapy.
Observation:
- A 58-year-old male presented with atypical multiple sclerosis (MS).
- The patient received subcutaneous thymopentin (50 mg/day) in cycles, 12 years after disease onset and following prior cortisone/ACTH treatments.
- Diagnostic evaluations included CAT-NMR, immunological tests, and isoelectrofocusing, confirming a demyelinating syndrome.
Findings:
- Thymopentin treatment resulted in significant clinical improvement, particularly in 'sthenia' (vitality) and motor function.
- The patient regained lost personal autonomy and work capacity.
- Immunological monitoring revealed subtle but notable changes in DNA parameters and HLA antigen binding to lymphocytes, suggesting immune system sensitivity to thymopentin.
Implications:
- These findings suggest thymopentin, a thymic hormone, may be a viable immunomodulatory treatment for certain MS cases.
- The study highlights the potential of immunomodulators in managing complex or late-onset demyelinating diseases.
- Further research into thymic hormone therapy for multiple sclerosis is warranted.